IL112572A0 - Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions - Google Patents

Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions

Info

Publication number
IL112572A0
IL112572A0 IL11257295A IL11257295A IL112572A0 IL 112572 A0 IL112572 A0 IL 112572A0 IL 11257295 A IL11257295 A IL 11257295A IL 11257295 A IL11257295 A IL 11257295A IL 112572 A0 IL112572 A0 IL 112572A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
nmda blocking
compositions
effective
dexanabinol derivatives
Prior art date
Application number
IL11257295A
Other languages
English (en)
Original Assignee
Ramot University Authority Ltd
Zissum Research Dev Co
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot University Authority Ltd, Zissum Research Dev Co, Pharmos Corp filed Critical Ramot University Authority Ltd
Publication of IL112572A0 publication Critical patent/IL112572A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL11257295A 1994-02-07 1995-02-07 Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions IL112572A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/192,886 US5521215A (en) 1989-11-07 1994-02-07 NMDA-blocking pharmaceuticals

Publications (1)

Publication Number Publication Date
IL112572A0 true IL112572A0 (en) 1995-05-26

Family

ID=22711431

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11257295A IL112572A0 (en) 1994-02-07 1995-02-07 Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions

Country Status (10)

Country Link
US (1) US5521215A (enExample)
EP (1) EP0765160B1 (enExample)
JP (1) JPH09511493A (enExample)
AT (1) ATE237324T1 (enExample)
AU (1) AU690221B2 (enExample)
CA (1) CA2183466A1 (enExample)
DE (1) DE69530389T2 (enExample)
IL (1) IL112572A0 (enExample)
SG (1) SG49625A1 (enExample)
WO (1) WO1995020958A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
AU733880B2 (en) 1996-09-27 2001-05-31 Eisai Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
JP2002501510A (ja) * 1997-05-07 2002-01-15 ユニメッド・ファーマシューティカルズ・インコーポレーテッド ヒトにおける攪乱行動を改善し気分を高揚させる方法
WO1999000129A1 (en) * 1997-06-30 1999-01-07 Dreyer Evan B Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
AU9797598A (en) * 1997-11-14 1999-06-07 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
JP2002512188A (ja) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
ATE247097T1 (de) * 1998-05-04 2003-08-15 Univ Connecticut Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6995187B1 (en) 1999-10-18 2006-02-07 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
WO2001098289A1 (en) * 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2435409A1 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
DE60237431D1 (de) 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
DE60234246D1 (de) * 2001-04-06 2009-12-17 Univ Illinois Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
CA2452881C (en) * 2001-07-13 2012-03-06 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US7029918B2 (en) * 2002-01-25 2006-04-18 Roche Diagnostics Operations, Inc. Water-soluble derivatives of lipophilic drugs
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
WO2004021974A2 (en) * 2002-09-05 2004-03-18 Pharmos Corporation Non-psychotropic cannabinoids for prevention of cognitive impairment
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
JP2006509038A (ja) * 2002-12-04 2006-03-16 ファーモス コーポレイション 医薬組成物用の高エナンチオマー純度を有するデキサナビノール
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
ZA200802767B (en) 2005-09-29 2009-09-30 Amr Technology Inc Process for production of delta-9-tetrahydrocannabinol
US8293786B2 (en) * 2007-07-30 2012-10-23 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
EP3654942A1 (en) 2017-07-20 2020-05-27 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Pharmaceutical film compositions for delivery of lipophilic compounds into and/or across the skin
EP3681474B1 (en) 2017-09-11 2025-10-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for nasal administration of drugs to brain and for systemic effect
WO2019106652A1 (en) 2017-11-29 2019-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoids compositions and methods
WO2020089905A1 (en) 2018-11-04 2020-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Orally administrable cannabinoids-containing compositions and methods
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464695A (en) * 1974-06-24 1977-02-16 Smithkline Corp Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4133819A (en) * 1977-06-17 1979-01-09 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4209520A (en) * 1977-06-17 1980-06-24 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO1995020958A1 (en) 1995-08-10
EP0765160A4 (enExample) 1997-04-09
SG49625A1 (en) 1998-06-15
DE69530389T2 (de) 2004-03-25
US5521215A (en) 1996-05-28
EP0765160B1 (en) 2003-04-16
EP0765160A1 (en) 1997-04-02
CA2183466A1 (en) 1995-08-10
AU1743395A (en) 1995-08-21
DE69530389D1 (de) 2003-05-22
AU690221B2 (en) 1998-04-23
ATE237324T1 (de) 2003-05-15
JPH09511493A (ja) 1997-11-18

Similar Documents

Publication Publication Date Title
IL112572A0 (en) Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions
EP1299374A4 (en) NEW NON PSYCHOTROPICAL CANNABINOIDS
BG101118A (en) Therapeutical compounds
IL115245A0 (en) Tumor necrosis factor inhibiting pharmaceuticals
SI0725779T1 (enExample)
TW362973B (en) Use of 2-anino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a composition having an antidepressant activity
CA2243404A1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
CA2215470A1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
AU2030497A (en) Propynyl or dienyl biaromatic compounds
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
GEP20032914B (en) Derivatives of 1,3,4-Oxadiazolone
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
EP0744176A3 (en) Methods for inhibiting bone loss
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
MY115795A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
EP1785417A3 (en) Novel non-psychotropic cannabinoids
MXPA02003731A (es) Derivados novedosos de acido fusidico.
AU2626392A (en) Use of substituted pyrrolidines, some of which are known, as medicaments, new active substances and processes for their preparation
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
PT986390E (pt) Composicoes farmaceuticas que contem cicloridrato de cinchonina
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.

Legal Events

Date Code Title Description
FF Patent granted